“The Andhra Pradesh Industrial Infrastructure Corporation (APIIC) has
allotted 10 acres to the company in phase III of the Genome Valley biotech park
on the city outskirts, and we expect to start commercial production in 18 to 24
months from now,†said DK Dey, general manager (biotechnology), Globion India.
The facility will have a capacity of 5,000 million doses per year and
produce multiple vaccines for dreadful poultry diseases including mareks,
infectious bronchitis and infectious bursal disease.
“Suguna felt it was essential to start vaccine manufacturing to cater to
the needs of the poultry farmers across the country and ensure import
substitution,†Dey said.
The group is the largest importer of poultry vaccines in India.
